$ANTX AN2 Therapeutics has been awarded a $3.8 million National Institutes of Health contract option for development of Epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens.https://t.co/ui7Dvv3Kr1
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.